Is Suboxone Safe with Ketamine Therapy?

If you're on Suboxone (buprenorphine/naloxone) and considering at-home ketamine therapy, the combination is structurally similar to the Methadone conversation we cover separately, but with a different patient population and a different care-coordination model. The verdict is case-by-case, depending on the stability of your Suboxone treatment, whether your primary current clinical question is depression or active OUD, and the relationship with your buprenorphine prescriber. The published evidence on this combination is more direct and more encouraging than for many other patient subgroups in this directory: a 2025 randomized clinical trial specifically tested ketamine alongside buprenorphine in patients with co-occurring MDD and OUD and found both produced meaningful reductions in anxiety and craving with no safety signals.

Suboxone vs Methadone: what's different

The Methadone page covers the broader framework for OUD-treatment medications combined with ketamine. Suboxone shares the framework but differs in a few practical ways worth knowing.

Pharmacology: Buprenorphine is a partial mu-opioid agonist (vs methadone's full agonism), with a ceiling effect on respiratory depression. This translates to a meaningfully safer overdose profile and less CNS depression stacking concern when combined with other sedating medications. Methadone is well-known to prolong the QT interval at higher doses; buprenorphine does not meaningfully prolong QT. Two of the three cardiovascular concerns that shape the Methadone intake conversation are minimal or absent for Suboxone.

Care delivery model: Methadone for OUD is dispensed through federally regulated opioid treatment programs (OTPs) with specific monitoring requirements. Suboxone is typically prescribed by individual physicians with a buprenorphine waiver, often in outpatient psychiatry, primary care, or addiction medicine settings. Coordination at Tovani happens via your prescribing physician directly rather than through an OTP, which is structurally similar but operationally easier.

Patient population: Suboxone patients are often at a different point in the OUD treatment trajectory than methadone patients. Many have stabilized on Suboxone after a previous methadone course, after office-based induction, or as their first MOUD attempt. The early-recovery population on Suboxone is meaningfully different from the long-term methadone-maintenance population in terms of depression-treatment readiness and the structure of the surrounding care.

The three subgroups

Subgroup 1: Active OUD with recent destabilization or illicit use

Patients with recent missed Suboxone doses, recent illicit opioid use, positive urine drug screens for non-prescribed substances, or recent dose instability are not currently candidates for at-home ketamine at Tovani. The same pathway applies as for methadone: stabilize first in coordination with your buprenorphine prescriber, demonstrate 6 or more months of stable engagement, and revisit the ketamine question for co-morbid depression that hasn't resolved with stabilization alone.

Subgroup 2: Stable long-term Suboxone maintenance + co-morbid depression

Patients who have been on Suboxone for more than 12 months, are dose-stable with no recent adjustments, have no missed doses or positive UDS findings for non-prescribed substances, have an active and engaged relationship with their buprenorphine prescriber, and are now asking about ketamine because depression has persisted despite Suboxone treatment producing stability in their opioid use.

For this subgroup, ketamine therapy is reasonable to consider and the published evidence is supportive. The 2025 Mansoori et al. RCT in Trials (PMID 40247293) specifically randomized 60 inpatients with co-occurring MDD and OUD to single-dose IV ketamine versus sublingual buprenorphine 16 mg. Both groups showed significant reductions in anxiety and craving with no statistically significant between-group difference and no safety signals; ketamine produced more rapid effects (within hours), buprenorphine more gradual but sustained (days). The trial framing was "both are promising treatments in this comorbid population," not "the combination is dangerous."

The Shen et al. 2025 scoping review in Frontiers in Psychiatry synthesized 8 studies on ketamine in OUD and opioid withdrawal and concluded ketamine "appears to be a helpful treatment," particularly in facilitating buprenorphine initiation. They noted that existing studies used ketamine as a replacement rather than an adjunct to standard MOUD, leaving the adjunctive question (most relevant to subgroup 2 at Tovani) as a research gap, but the early signal is supportive.

The operational requirement at Tovani is mandatory coordination with your buprenorphine prescriber. We ask for a release of information, communicate directly with your prescriber, confirm dose stability and ongoing engagement, and expect your prescriber to remain your primary addiction-medicine care relationship while we treat the depression.

Subgroup 3: Suboxone for chronic pain (off-label or older patient)

Suboxone is occasionally prescribed off-label for chronic pain, particularly in patients who have not tolerated traditional opioids or in palliative care contexts. Buprenorphine films and patches (Butrans) are also FDA-approved for chronic pain. For these patients, the conversation looks similar to any chronic pain patient on long-term opioid therapy: confirm the prescribing physician and indication, review for other concurrent medications, and proceed with standard ketamine onboarding. Many of these patients are excellent ketamine candidates specifically because they have refractory depression in the context of chronic pain, and ketamine has dual action.

The cardiovascular and CNS-depression concerns, briefly

For buprenorphine specifically, the cardiovascular concerns are smaller than for methadone. Buprenorphine does not meaningfully prolong the QT interval at therapeutic doses; the partial agonist activity means a ceiling on respiratory depression that limits the worst-case scenario of CNS depression stacking. The Veraart 2021 systematic review did not flag this combination as a documented case-series risk, and the Mansoori 2025 RCT (which specifically combined the two in monitored inpatient settings) reported no safety signals.

At-home Tovani applies the same general conservatism we do for other CNS-active combinations: standard onboarding, attention to other concurrent sedating medications, sober support person present during sessions. We do not currently require routine ECG or vital-sign monitoring beyond what we do for any ketamine patient when buprenorphine is the only relevant comorbidity.

What we do at intake

When a patient is on Suboxone, our intake process layers a few confirmations on top of standard eligibility screening:

The indication for Suboxone (OUD vs chronic pain) and duration of treatment.

Dose stability for at least 6 months at the current Suboxone dose.

Recent UDS history (no positives for non-prescribed substances for at least 6 months in subgroup 2).

The prescribing physician and the existing relationship structure. We ask for a release of information and a brief conversation or fax exchange with your prescriber confirming stability.

Recent mental health treatment history, including any psychiatry or therapy relationships that will continue alongside ketamine.

For most stable subgroup 2 patients with engaged prescriber care, intake completes within standard timelines and ketamine onboarding proceeds.

Why care coordination is non-negotiable

The same reasoning as for methadone applies. OUD treatment is a structured care model with specific monitoring requirements, and your buprenorphine prescriber is your primary addiction-medicine care relationship. Tovani treating depression in this patient does not replace the prescriber relationship; it complements it. The prescriber needs to know about ketamine treatment so they can interpret any changes in urine drug screens, dose tolerability, or clinical presentation in context. Tovani needs to confirm with the prescriber that Suboxone maintenance is stable, doses are not being missed, and the patient is engaged in structured OUD care. If anything unexpected happens with either treatment, both providers need to be in the loop in real time.

Patients whose buprenorphine prescriber cannot or will not coordinate are referred to clinic-based or integrated-care programs that have addiction medicine and ketamine on the same team. We don't operate that kind of program at Tovani.

Bottom line

Suboxone with at-home ketamine is genuinely case-by-case. Active OUD with recent destabilization is effectively not a candidate at Tovani's at-home model, with a clear pathway: stabilize first, demonstrate 6 or more months of engagement, then revisit. Stable long-term Suboxone maintenance with co-morbid depression is a reasonable ketamine candidate with mandatory coordination with the buprenorphine prescriber; the published evidence (Mansoori 2025, Shen 2025) is supportive of this combination in monitored settings and our care-coordination requirement is how we approximate that monitoring layer through prescriber relationships. Suboxone for chronic pain with no current OUD is the most flexible subgroup. Patients should not stop Suboxone to access ketamine; Suboxone discontinuation is a major clinical decision that belongs entirely between the patient and their prescribing physician.